最新更新 :
19/11/2024
抗生素   Rifampicin  
注射液
口服剂
溶液稳定性 混合物稳定性 影响稳定性的因素 兼容性 用药途径 引用文献 PDF
   化学式  

商品名   商品名     

商品名仅供参考, 药品所用的辅料可能依国家或厂商不同有所不同。

Eremfat 奥地利, 德国
Rif 土耳其
Rifa 德国
Rifadin 伊朗, 意大利, 新西蘭, 澳大利亚, 爱尔兰, 瑞典, 美国, 英国, 荷兰
Rifadine 摩洛哥, 比利时, 法国
Rifaldin 伊朗, 西班牙
Rifampicin 德国
Rifampicina 厄瓜多尔, 阿根廷
Rifampin 美国
Rifoldin 奥地利
Rimactan 瑞士
Rimactane 爱尔兰
引用文献   注射液   引用文献 : Rifampicin  
种类 出版物
198 文献 Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
263 文献 Pearson SD, Trissel LA.
Stability and compatibility of minocycline hydrochloride and rifampicin in intravenous solutions at various temperatures.
Am J Hosp Pharm 1993 ; 50: 698-702.
2139 文献 Serrurier C, Chenot ED, Vigneron J, May I, Demor? B.
Assessment of injectable drug’s administration in two intensive care units and determination of potential physico-chemical incompatibilities.
EJHP Science 2006 ; 12,5: 96-99.
3379 文献 Fox L.M, Wilder A.G, Foushee J.A.
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Am J Health-Syst Pharm 2013 ;70:520-524.
3541 实验室 Rifampicin (Rifadin®) – Summary of Product Characteristics
Sanofi 2011
4405 文献 Ezquer-Garin C, Ferriols-Lisart R, Martinez-López LM, Sangrador-Pelluz C, Nicolás-Picó J, Alós-Almiñana M.
Stability of tedizolid phosphate-sodium rifampicin and tedizolid phosphate-meropenem admixtures in intravenous infusion bags stored at different temperatures
Pharmazie 2020 ; 75: 172-176.
4543 文献 Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4837 文献 De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T.
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
Eur J Clin Pharmacol 2024 ; 80:1079–1087.

  Mentions Légales